Pfizer (PFE)
24.27
+0.39 (1.63%)
NYSE· Last Trade: Jul 2nd, 4:09 PM EDT
Analysts have given Alnylam Pharmaceuticals an average price target of $436.
Via The Motley Fool · July 2, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · July 2, 2026
These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.
Via The Motley Fool · July 1, 2026
Most active S&P500 stocks in Wednesday's sessionchartmill.com
Via Chartmill · June 24, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...
Via StockStory · June 30, 2026
Maximize your investment opportunities in US stocks with a TFSA while being aware of the tax implications of dividends.
Via The Motley Fool · June 30, 2026
Looking for the most active stocks in the S&P500 index on Tuesday?chartmill.com
Via Chartmill · June 30, 2026
It could prove to be a case of better later than never for the healthcare giant.
Via The Motley Fool · June 30, 2026
Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.
Via The Motley Fool · June 30, 2026
Nike is set to report earnings on June 30. Here's what to expect.
Via The Motley Fool · June 30, 2026
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
Via The Motley Fool · June 29, 2026
Why settle for puny yields when you can buy these monster dividend stocks?
Via The Motley Fool · June 29, 2026
Things are going from bad to worse for the pharmaceutical giant.
Via The Motley Fool · June 28, 2026
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Via The Motley Fool · June 27, 2026
Take advantage of short-term weakness by stepping into the right long-term investments when they go on sale.
Via The Motley Fool · June 27, 2026
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
Via The Motley Fool · June 27, 2026
With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.
Via The Motley Fool · June 27, 2026
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Via The Motley Fool · June 25, 2026
Novo Nordisk is no longer the front-runner, but it's not out of the running, either.
Via The Motley Fool · June 25, 2026
The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.
Via Benzinga · June 25, 2026
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
Via StockStory · June 25, 2026
Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the
Via Talk Markets · June 24, 2026
Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.
Via Benzinga · June 24, 2026
Don't wait until they recover to initiate positions.
Via The Motley Fool · June 23, 2026
